Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
By A. Burnett, R. Hills, D. Milligan, L. Kjeldsen, J. Kell, N. Russell, John A. Yin, A. Hunter, A. Goldstone, K. Wheatley. Journal of Clinical Oncology, 2011
621 citations recorded by the source corpus.
Subfields: Hematology, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/8b226d8841933468afd62e060e0c1705467d1b9c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. (2013, positive): “The MRC AML 15 study included 1113 patients who were randomly assigned to receive 3 mg/m(2) of GO on day 1 of induction with DA, DA plus etoposide, or fludarabine, cytarabine, G-CSF, and idarubicin.(14) Those randomly assigned to GO also received the drug during consolidation.”
- Antibody drug conjugate: the “biological missile” for targeted cancer therapy (2022, background): “Based on the overall positive outcomes achieved in above three investigator-led clinical trials, thus the Mylotarg was re-approved by the FDA in 2017.(149,151,152) Recently, a new indication of gemtuzumab ozogamicin was approved by the FDA for the treatment of newly-diagnosed CD33-positive AML to in”